Levomilnacipran

This is a type of medicine called an antidepressant. It helps people who are feeling very sad or hopeless. It works by affecting chemicals in the brain that help control mood.

Brand names:Fetzima
Medication

What people taking Levomilnacipran report

Every report comes from a Lived member, sent anonymously.

Have you tried Levomilnacipran for Depression?

NameHow it went

About Levomilnacipran

What It's For

Levomilnacipran, sold in the US under the brand name Fetzima, is a prescription antidepressant approved to treat major depressive disorder (the medical term for clinical depression) in adults. It belongs to a group of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs). It is not approved for children or teenagers. Levomilnacipran is one of the two mirror-image forms that make up milnacipran, a related medicine sold as Savella for fibromyalgia. Despite that close relationship, levomilnacipran has not been shown to work for fibromyalgia and is not approved for it, and the two products are not interchangeable.

How It Works

Serotonin and norepinephrine are chemical messengers that brain cells use to signal one another, and both are involved in regulating mood. After a messenger carries its signal, the sending cell normally pulls it back in, a process called reuptake. Levomilnacipran blocks the reuptake of both messengers, leaving more of each available between nerve cells. In laboratory tests it blocks norepinephrine reuptake at least as strongly as serotonin reuptake. Norepinephrine also acts outside the brain, which helps explain why this medicine can raise heart rate and blood pressure and make urination harder to start. The reuptake change happens quickly, but exactly how it relieves depression is not known.

Dosage & Administration

Fetzima comes as extended-release capsules, designed to release the medicine gradually through the day. It is taken once a day at about the same time, with or without food. Treatment usually starts at 20 mg for two days and then 40 mg daily. Depending on response and side effects, the prescriber may raise the dose in 40 mg steps, up to a maximum of 120 mg a day. A starter pack holds the first few weeks of 20 mg and 40 mg capsules. Swallow the capsules whole; do not open, chew or crush them. The kidneys clear most of the drug, so people with moderate or severe kidney disease have a lower maximum dose, and it is not recommended for people with end-stage kidney disease. Liver disease does not require a dose change. If a dose is missed, take it when remembered unless the next dose is nearly due; never take two doses together. Do not stop levomilnacipran suddenly. Lowering the dose gradually with the prescriber helps avoid discontinuation symptoms such as dizziness, irritability, anxiety, headache, trouble sleeping and brief electric-shock sensations.

Side Effects

The most common side effects in clinical trials were nausea, constipation, heavy sweating, a faster heartbeat or palpitations (a feeling that the heart is pounding or racing), and vomiting. Nausea affected about 17% of people taking it, compared with 6% on placebo, and was the side effect that most often led people to stop. In men, erectile dysfunction and trouble ejaculating were common, and erectile problems became more frequent at higher doses. Women can also have lower sexual desire or delayed orgasm. Sexual side effects are worth raising with the prescriber, since some can be managed. Blood pressure and heart rate tend to rise. In trials, heart rate went up by about 7 beats per minute on average. The prescriber checks both before starting and during treatment, and high blood pressure should be under control first. A sustained rise may mean changing the dose or the medicine. Some people have trouble starting urination, which was more common at higher doses; a weak stream or being unable to pass urine should be reported. Less often, levomilnacipran can set off angle-closure glaucoma, a sudden rise in eye pressure, in people whose eyes have narrow drainage angles. Eye pain, vision changes, or redness or swelling around the eye should be reported promptly. Low blood sodium can also develop, especially in older adults and people taking diuretics (water pills); headache, confusion, trouble concentrating, weakness or unsteadiness can be signs and are worth reporting.

Interactions & Warnings

Like other antidepressants, levomilnacipran carries a boxed warning from the US Food and Drug Administration (FDA), its most prominent warning: in short-term studies, antidepressants increased suicidal thoughts and behaviors in children, teenagers and young adults up to age 24. At any age, new or worsening depression, agitation, restlessness, unusual changes in behavior or thoughts of suicide, particularly in the first few months or after a dose change, should be reported to the prescriber right away. Acting on suicidal thoughts or dangerous impulses needs emergency help right away. Levomilnacipran must not be combined with an MAOI (monoamine oxidase inhibitor, an older type of antidepressant), including the antibiotic linezolid or intravenous methylene blue (a dye given by vein in some hospital procedures and treatments). At least 14 days must pass after stopping an MAOI before starting levomilnacipran, and at least 7 days after stopping levomilnacipran before starting an MAOI. These combinations can cause serotonin syndrome, a potentially life-threatening reaction to too much serotonin activity. The risk is also higher with other medicines that raise serotonin, including other antidepressants, triptans for migraine, tramadol and other opioid pain medicines, lithium (a mood stabilizer used mainly for bipolar disorder), buspirone (an anxiety medicine), amphetamine stimulants and the herbal supplement St. John's wort. Agitation, confusion, hallucinations, a racing heart, high body temperature, heavy sweating, stiff or twitching muscles, or a seizure call for emergency care right away. Aspirin, ibuprofen and other NSAIDs (nonsteroidal anti-inflammatory pain relievers), and warfarin or other blood thinners, add to a bleeding risk this medicine already carries; unusual bleeding or bruising should be reported promptly. Avoid alcohol: in laboratory tests, alcohol made the capsules release the drug much faster than designed. Some antibiotics and antifungal medicines, such as clarithromycin and ketoconazole, raise levomilnacipran levels, so the prescriber may limit the dose. Before starting, the prescriber should know about high blood pressure, heart rhythm problems or past stroke, glaucoma, trouble urinating, seizures, kidney disease, and any personal or family history of bipolar disorder. In people prone to it, an antidepressant can trigger mania, a period of unusually high energy, little need for sleep, racing thoughts or reckless behavior. Levomilnacipran can also cause sleepiness or slow reactions, so driving should wait until a person knows how it affects them. Data on levomilnacipran in pregnancy are limited. Taking an SNRI late in pregnancy has been linked to heavier bleeding after delivery and to breathing, feeding and temperature problems in newborns, while stopping an antidepressant during pregnancy raises the chance of depression returning. It is not known whether levomilnacipran passes into breast milk, although the closely related milnacipran does. Anyone pregnant, planning pregnancy or breastfeeding should weigh these trade-offs with the prescriber rather than stopping on their own.

What to Expect

In the eight-week studies that led to approval, people taking levomilnacipran improved by about 14 to 16 points on a 60-point depression rating scale, compared with about 11 to 12 points for people taking placebo. Much of that improvement also happened on placebo with regular study care; the medicine added about 3 to 4 points on average beyond it. Everyday functioning at work, at home and socially also improved more than with placebo. Those are group averages; individual responses vary, and side effects can show up before benefit does. Benefit is judged over several weeks rather than days, so an early lack of change does not by itself mean the medicine has failed. The prescriber may adjust the dose over the first weeks, and early visits usually include blood pressure and heart rate checks along with a review of mood and side effects. If it works, continuing after symptoms improve helps keep depression from returning. In a study of people who had responded, those who stayed on levomilnacipran went longer without a relapse than those switched to placebo. How long to continue depends on a person's history and response, and stopping is done gradually. If it does not help enough or is hard to tolerate, a different dose or another treatment may be the next step.

Questions to Ask Your Doctor

  1. 1.Why might levomilnacipran suit me better than a selective serotonin reuptake inhibitor (SSRI) or another SNRI, given my symptoms and past treatments?
  2. 2.How often will we check my blood pressure and heart rate, and what changes would make us reconsider the dose?
  3. 3.Do any of my current medicines, migraine treatments, pain relievers or supplements interact with it?
  4. 4.When should I expect to know whether it is working, and what is our plan if it is not?
  5. 5.How long should I plan to stay on it, and how would we taper it when the time comes?

Last reviewed • Oct 2026

Educational content, not medical advice.